PTO/SB/08A (10/01) (modified) U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Substitute for form 1449A/PTO **Application Number** 10/762.388 **Filing Date** January 22, 2004 INFORMATION DISC First Named Inventor James L. Madara STATEMENT BY APPLICANT **Art Unit** Unknown (use as many sheets as necessary) **Examiner Name** Unknown **Sheet** of 4 **Attorney Docket Number** 7210.03 **U.S. PATENT DOCUMENTS** Pages, Columns, Lines, Where Cite DOCUMENT NUMBER **Publication Date** Name of Patentee or Relevant Passages or Initials Number - Kind Code (if known) MM-DD-YYYY **Applicant of Cited Document** Relevant Figures Appear 5,441,951 8-1995 Serhan US-2~(. 5,648,512 7-1997 Serhan US-6.353.026 3-2002 Serhan 2. US-6,458,839 10-2002 Madara et al. US-Z 6.699.905 3-2004 Madara et al. US-US-FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENT TRANSLATION Country Number - Kind Code Pages, Columns, Lines, Cite **Publication Date** *Examiner Code: (if known) Name of Patentee or Where Relevant Passages Initiat MM-DD-YYYY Applicant of Cited Document or Relevant Figures Appear NO PCT WO 94/29262 12-1994 PCT WO 95/01179 1-1995 PCT WO 00/54767 9-2000 **OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS** include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the TRANSLATION Cte item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue Initials number(s), publisher, city and/or country where published YES Weissmann, G., Smolen, J. E., and Korchak, H. M. (1980) Release of inflammatory mediators from stimulated neutrophils. N. Engl. J. Med. 303, 27-34 Serhan, C. N., Haeggstrom, J. Z., and Leslie, C. C. (1996) Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J. 10, 1147-1158 Weiss, S. J. (1989) Tissue destruction by neutrophils. N. Engl. J. Med. 320, 365-376 Serhan, C. N. (1994) Lipoxin biosynthesis and its impact in inflammatory and vascular events.

Borgeat, P., and Naccache, P. H. (1990) Biosynthesis and biological activity of leukotriene B4.

Biochim. Biophys. Acta 1212, 1-25

Clin. Biochem. 23, 459-468

Substitute for form 1449A/PTO					Application Number	10/762,388				
INFORMATION DISCLOSURE				NCOLOCUDE	Filing Date	January 22, 2004				
STATEMENT BY APPLICANT (use as many sheets as necessary)					First Named Inventor	James L. Madara				
					Art Unit	Unknown				
					Examiner Name	Unknown				
Sheet		2	of	4	Attorney Docket Number	7210.03				
		ОТ	HERI	DOCUMENTS - NOI	N-PATENT LITERATUR	E DOCUMENTS				
26					kuwa, T., and Shimizu, T. (1 chemotaxis. <i>Nature</i> 387, 620					
24			Fiore, S., Romano, M., Reardon, E. M., and Serhan, C. N. (1993) Induction of functional lipoxin A ₄ receptors in HL-60 cells. <i>Blood</i> 81, 3395-3403							
2-6			Isakson, P., Seibert, K., Masferrer, J., Salvemini, D., Lee, L., and Needleman, P. (1995) Discovery of a better aspirin. <i>Advances in Prostaglandin, Thromboxane & Leukotriene Research</i> 23, 49-54							
2.5	-	Chiang, N., Takano, T., Clish, C. B., Petasis, N. A., Tai, HH., and Serhan, C. N. (1998) Aspirintriggered 15-epi-lipoxin A ₄ (ATL) generation by human leukocytes and murine peritonitis exudates: development of a specific 15-epi-LXA ₄ ELISA. <i>J. Pharmacol Exper. Ther.</i> 287, 779-790								
26		Serhan, C. N., Maddox, J. F., Petasis, N. A., Akritopoulou-Zanze, I., Papayianni, A., Brady, H. R., Colgan, S. P., and Madara, J. L. (1995) Design of lipoxin A ₄ stable analogs that block transmigration and adhesion of human neutrophils. <i>Biochemistry</i> 34, 14609-14615								
Zuf		Takano, T., Fiore, S., Maddox, J. F., Brady, H. R., Petasis, N. A., and Serhan, C. N. (1997) Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 Stable analogues are potent inhibitors of acute inflammation: Evidence for anti-inflammatory receptors. J. Exp. Med. 185, 1693-1704								
2.5		Owman, C., Garzino-Demo, A., Cocchi, F., Popovic, M., Sabirsh, A., and Gallo, R. (1998) The leukotriene B ₄ receptor functions as a novel type of coreceptor mediating entry of primary HIV-1 isolates into CD4-positive cells. <i>Proc. Natl. Acad. Sci.</i> 95, 9530-9534								
2.5		Marcus, A. J. (1995) Aspirin as prophylaxis against colorectal cancer. N. Engl. J. Med. 333, 656-658								
2.f		Vainio, H., and Morgan, G. (1997) Aspirin for the second hundred years: new uses for an old drug. <i>Pharmacol Toxicol</i> 81, 151-152								
Zr.F		Herschman, H. R. (1998) Recent progress in the cellular and molecular biology of prostaglandin synthesis. <i>Trends in Cardiovasc. Med.</i> 8, 145-150								
Zif		Takano, T., Clish, C. B., Gronert, K., Petasis, N., and Serhan, C. N. (1998) Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epilipoxin A ₄ and novel lipoxin B ₄ stable analogues. <i>J. Clin. Invest.</i> 101, 819-826								
2-1	•	Billah, M. M., Eckel, S., Mullmann, T. J., Egan, R. W., and Siegel, M. I. (1989) Phosphatidylcholine hydrolysis by phospholipase D determines phosphatidate and diglyceride levels in chemotactic peptide-stimulated human neutrophils. Involvement of phosphatidate phosphohydrolase in signal transduction. <i>J. Biol. Chem.</i> 264, 17069-17077								
2,5	_	Wakelam, M. J. O., Martin, A., Hodgkin, M. N., Brown, F., Pettit, T. R., Cross, M. J., De Takats, P. G., and Reynolds, J. L. (1997) Role and regulation of phospholipase D activity in normal and cancer cells. <i>Advances in Enzyme Regulation</i> 37, 29-34								

8-- -

Substitute for form 1449A/PTO					Application Number	10/762,388				
INFORMATION DISCLOSURE				ISCI OSUBE	Filing Date	January 22, 2004				
STATEMENT BY APPLICANT					First Named Inventor	James L. Madara				
(use as many sheets as necessary)					Art Unit	Unknown				
(abb as many sheets as movestary)					Examiner Name	Unknown				
Sheet		3	of	4	Attorney Docket Number	7210.03				
OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS										
Zif		Olson, S. human ne	C., and eutrophi	Lambeth, J. D. (1996) ils. <i>Chem. Phys. Lipids</i> (liochemistry and cell biology of phospholipase D in 0, 3-19					
214		Steed, P. M., Clark, K. L., Boyar, W. C., and Lasala, D. J. (1998) Characterization of human PLD2 and the analysis of PLD isoform splice variants. <i>FASEB J.</i> 12, 1309-1317								
25		Wakelam,	Martin, A., Saqib, K. M., Hodgkin, M. N., Brown, F. D., Pettit, T. R., Armstrong, S., and Wakelam, M. J. O. (1997) Role and regulation of phospholipase D signalling. <i>Biochem. Soc. Trans.</i> 25, 1157-1160							
25		Levy, B. C signalling.	Levy, B. D., Petasis, N. A., and Serhan, C. N. (1997) Polyisoprenyl phosphates in intracellular signalling. <i>Nature</i> 389, 985-989							
2 f		Agwu, D. E., McPhail, L. C., Sozzani, S., Bass, D. A., and McCall, C. E. (1991) Phosphatidic acid as a second messenger in human polymorphonuclear leukocytes. Effects on activation of NADPH oxidase. <i>J. Clin. Invest.</i> 88, 531-539								
S. L		Pettit, T. R., Martin, A., Horton, T., Liossis, C., Lord, J. M., and Wakelam, M. J. O. (1997) Diacylglycerol and phosphatidate generated by phospholipases C and D, respectively, have distinct fatty acid compositions and functions. <i>J. Biol. Chem.</i> 272, 17354-17359								
24		Gomez-Cambronero, J. (1995) Immunoprecipitation of a phospholipase D activity with antiphosphotyrosine antibodies. <i>J. Interferon Cytokine Res.</i> 15, 877-885								
Zif		Abousalham, A., Riviere, M., Teissere, M., and Verger, R. (1993) Improved purification and biochemical characterization of phospholipase D from cabbage. <i>Biochim. Biophys. Acta</i> 1158, 1-7								
2f		Zhou, HL., Chabot-Fletcher, M., Foley, J. J., Sarau, H. M., Tzimas, M. N., Winkler, J. D., and Torphy, T. J. (1993) Association between leukotriene B ₄ -induced phospholipase D activation and degranulation of human neutrophils. <i>Biochem. Pharmacol.</i> 46, 139-148								
24		Shechter, I., Fogelman, A. M., and Popjak, G. (1980) A deficiency of mixed function oxidase activities in the cholesterol biosynthetic pathway of human granulocytes. <i>J. Lipid Res.</i> 21, 277-283								
2.6		Rabinowitz, J. L., Baker, D. G., Villanueva, T. G., Asanza, A. P., and Capuzzi, D. M. (1992) Liver lipid profiles of adults taking therapeutic doses of aspirin. <i>Lipids</i> 27, 311-314								
Sif		Claria, J., and Serhan, C. N. (1995) Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. <i>Proc. Natl. Acad. Sci.</i> 92, 9475-9479								
5.5		Serhan, C. N. (1997) Lipoxins and Novel Aspirin-Triggered 15-epi-Lipoxins: A Jungle of Cell-Cell Interactions or a Therapeutic Opportunity? <i>Prostaglandins</i> 53, 107-137								
ZIF	_	Exton, J. H. (1997) New developments in phospholipase D. J. Biol. Chem. 272, 15579-15582								
2.6		Fensome, A., Whatmore, J., Morgan, C., Jones, D., and Cockcroft, S. (1998) ADP-ribosylation factor and Rho proteins mediate fMLP-dependent activation of phospholipase D in human neutrophils. <i>J. Biol. Chem.</i> 273, 13157-13164								

4 1 .

Substitute for form 1449A/PTO					Application Number	10/762,388				
INFORMATION DISCLOSURE					Filing Date	January 22, 2004				
					First Named Inventor	James L. Madara				
STATEMENT BY APPLICANT					Art Unit.	Unknown				
(use as many sheets as necessary)					Examiner Name	Unknown				
Sheet 4 of 4					Attorney Docket Number	7210.03				
OTHE	OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS									
26		squalene.	Jarstfer, M. B., Blagg, B. S. J., Rogers, D. H., and Poulter, C. D. (1996) Biosynthesis of squalene. Evidence for a tertiary cyclopropylcarbinyl cationic intermediate in the rearrangement of presqualene diphosphate to squalene. <i>J. Amer. Chem. Soc.</i> 118, 13089-13090							
2.5		Bach, T. J 191-202	Bach, T. J. (1995) Some new aspects of isoprenoid biosynthesis in plantsa review. <i>Lipids</i> 30,							
2,5		Serhan et al., "Aspirin-Triggered 15-EPI-Lipoxin A ₄ and Novel Lipoxin B ₄ Stable Analogs Inhibit Neutrophil-Mediated Changes in Vascular Permeability," <i>Advances in Experimental Medicine and Biology</i> , Vol. 469, 1999, pgs. 287-293								
Zif		Gewirzt et al., "Pathogen-Induced Chemokine Secretion from Model Intestinal Epithelium is Inhibited by Lipoxin A₄ Analogs", <i>Journal of Clinical Investigation</i> , Vol. 101, No. 9, May 1998, pgs. 1860-1869								
Zuf		Intracellula	Hansson et al., "Activation of Protein Kinase C By Lipoxin A and Other Eicosandoids. Intracellular Action of Oxygenation Products of Arachidonic Acid", <i>Biochemical and Biophysical Research Communications</i> , Vol. 134, No. 3, 1986, pgs. 1215-1222							
24		Olson et a	Olson et al., "Biochemistry and cell biology of phospholipase D in human neutrophils", Chemistry and Physics of Lipids, 80, pp. 3-19, 1996							
24		Application	Takano et al., "Neutrophil-mediated Changes in Vascular Permeability Are Inhibited by Topical Application of Aspirin-triggered 15-epi-lipoxin A ₄ and Novel Lipoxin B ₄ Stable Analogues", J. Clin. Invest. Volume 101, Number 4, February 1998, pp. 819-826							
•										
EXAMINER SIGNATURE Zolof For DATE CONSIDERED 8/20/05										
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through										

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

6iPE 2	
HIN 1 5 TOOK SE	PTO/SB/08A (10/01) (modified) U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute footerm 1449A/PTO						Appli	cation Number	10/762,388				
						Filing	Date	January 22, 2004				
INFORMATION DISCLOSURE						First	Named Inventor	James L. Madara				
STATEMENT BY APPLICANT						Art Unit		1614				
(use as many sheets as necessary)							niner Name	Unknown				
Sheet		1	of	1		Attor	ney Docket Number	7210.03				
U.S. PATENT DOCUMENTS												
*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)			Publication MM-DD-Y	Date	e Name of Patentee or				nt Passages or	
		US-										
		US-										
		UŞ-										
		US-										
		US-					ļ					
		US-			_		<u></u>					
		US-										
		US-										
		US-										
		US-										
		US-										
		US-										
		US-										
		US-			-		<u>. </u>					
	,	 		FC	REIGN P	ATEN	IT DOCUMENTS	Τ	_,	Γ		
*Examiner	Cite	FOREIGN PATENT DOCUMENT Country Number - Kind Code (if Date						Pages, Columns, Lines, Where Relevant Passages		TRANSLATION		
Initial	No.	Code:	known)		MM-DD-YYY	YYY A	Applicant of Cited Document		Figures Appear	YES	NO	
20		JP	63-178	325 	01-28-19	88 1	Геijin Ltd.	<u> </u>				
,					· .							
]											
								·				
EXAMINER SIGNATURE Zahlfay DATE CONSIDERED 8/20/05												
*EVANINED: Initial if reference appointment whether exact sitution is in conformance with MPER 600. Draw line through										nuah		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.